Immune Mediated Inflammatory Diseases – Targets, Technologies, Markets, Strategies, Forecasts

 

inflammatory pathway therapeutics  Immune Mediated Inflammatory Diseases •  December 2019  •  no. JMD984F •  Price US $2,850



 

Prior to the start of this century, a new treatment for rheumatic inflammatory diseases came along roughly once every 20 years. However, since then more than a dozen new drugs have been launched in a short time, all of which are based on major molecular breakthroughs on key molecules in the inflammatory process.  While the focus of first generation immunotherapeutic drugs centered on tumor necrosis factor inhibitors, recently approved immune modulators precisely target specific ligands and/or receptors of inflammatory pathways, resulting in diminished collateral impact while slowing down the production and release of inflammatory cytokines into the extracellular space. This report includes analysis of three-dozen approved therapeutic drugs and late-stage development candidates that target more that a dozen discreet pathway actors, effectively reducing the human inflammatory response with fewer side effects than earlier therapeutic options.

Bar_Graph Immune Mediated Inflammatory Disease Markets – Report Prospectus (Download PDF)

Blue document  Immune Mediated Inflammatory Diseases Report Order Form (Download PDF)

 

Click HERE to Order Online

 

 


Immune Mediated Inflammatory Diseases – What You Will Learn

  • What are the immune factors  that are responsible for immune mediated inflammatory diseases?
  • What are the inflammatory-mediated ligands, receptors, signaling proteins and transcription factors that represent druggable targets?
  • What are the major factors driving the high level of development activity in immune mediated inflammatory diseases?
  • What is the impact of pathway cross-talk in the pathology of conditions such as psoriasis and how will this affect sector therapeutic uptake?
  • What is the level of clinical trial activity in this sector, and who are the active participants?
  • What is the level of patent activity, who are the IP holders, and what targets/ pathway segments do they focus on?
  • What is the size of the market today, who are the market share leaders, and what will the market share be in 2022?
  • What are the significant economic, technology, and regulatory factors affecting the market for immune therapeutics

 


Immune Mediated Inflammatory Diseases – Summary of Contents

Executive Summary

Inflammatory Pathways
Inflammatory Pathway Cascade Targets

Cytokines
Interleukin 6 (IL-6)
Interleukin IL-6R
Interleukin-21 (IL-21)
Interleukin-21R (IL-21R)
Interleukin-23 (IL-23)
Interleukin-23R (IL-23R)
Interleukin-17A (IL-17A)
Interleukin-17C (IL-17C)
Interleukin 17A/17F
Interleukin-17RA (IL-17RA)
Interleukin 17
Interleukin-22 (IL-22)

Janus Kinase/Tyrosine Kinase Inhibitors
Signaling Proteins
Signal Transducer & Activator of Transcription

Transforming Growth Factor-β RI/RII (TGF-β RI/RII)
Retinoic acid-related orphan receptor RORyt

Market Status
Market Size

Competitive Landscape

Immune Mediated Market Assessment
Addressable Market
Competitive Landscape

Profiles of Market Participants